Identification Rate of Sentinel Lymph Node Biopsy using Single Technique (Isosulfan Blue Dye) in Early Breast Cancer in Lopburi Cancer Hospital

Authors

  • Kanchana Areerattanavet, M.D.

Keywords:

Lymphatic mapping, Sentinel lymph node, Breast cancer, Lopburi Cancer Hospital

Abstract

Background: Breast cancer is currently the most common cancer of woman in worldwide and also in Thailand. In the past, radical axillary surgery had been an integral part of breast cancer treatment to staging and provided locoregional control. During the past decade, surgical paradigm changed from standard axillary lymph node dissection for early breast cancer patients to sentinel lymph node biopsy (SLNB) due to increasing evidence indicated that was safe and acceptably accurate method for determining axillary node staging in early-stage breast cancer patients without clinically axilla lymph node involvement. Sentinel lymph node was identified by lymphatic mapping. There were 3 techniques of lymphatic mapping; blue dye alone, radioisotope alone, or a combination of blue dye and radioisotope. In this study, we used blue dye alone for lymphatic mapping due to simplicity and low cost.

Objective: The purpose of this study to report an identification rate of sentinel lymph node using isosulfan blue dye alone in breast cancer patients at Lopburi Cancer Hospital and to find out factors that might affect the rate of sentinel lymph node identification.

Methods: This study was retrospective observational study. Patients were enrolled between 1st August 2017 and 30th April 2020. Eligible criteria included T1 or T2 invasive breast cancer and all T size of ductal carcinoma in situ who underwent mastectomy, with all clinically negative axillary lymph nodes. All patients performed sentinel lymph node biopsy by using 1% isosulfan blue dye alone for lymphatic mapping at Lopburi Cancer Hospital.

Results: A total of 74 female breast cancer patients representing 75 cases (1 bilateral breast cancer case) underwent SLNB using isosulfan blue dye alone. A sentinel node was identified in 71 of 75 cases (94.67%).

Conclusion: The identification rate of sentinel lymph node biopsy using isosulfan blue dye alone in early breast cancer at Lopburi Cancer Hospital are acceptable and feasible.

Downloads

Download data is not yet available.

References

Imsamran W, Pattatang A, Supaattagorn P, Chiawiriyabunya I,Namthaisong K, Suwanrungruang K, et al.Cancer in Thailand:Vol. IX, 2013-2015. Bangkok (Thailand). Bangkok (Thailand): New Thammada Press; 2018.

Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer1989;63:181-7.

Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Edge SB,Galper S, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005 ;23:7703–20.

De Gournay E, Guyomard A, Coutant C, Boulet S, Arveux P,Causeret S, et al. Impact of sentinel node biopsy on long-term quality of life in breast cancer patients. Br J Cancer 2013;109:2783-91.

Newman EA, Newman LA. Lymphatic mapping techniques and sentinel lymph node biopsy in breast cancer.Surg Clin North Am 2007;87:353–64.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881–8.

Morrow M, Rademaker AW, Bethke KP, Talamonti MS, Dawes LG, Clauson J, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999;126:714–20.

Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4-16.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP,Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase3 trial. Lancet Oncol 2010;11:927-33.

McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD,Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multiinstitutional practice when optimal technique is used. J Clin Oncol 2000;18:2560-6.

Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localization and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase.Breast Cancer Res Treat 2006;99:203-8.

Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol.1993; 2:335-9.

Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph - nodes. Lancet 1997; 349:1864-7.

Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.

Giuliano AE, Jones RE, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.

The American Society of Breast Surgeons. Performance and Practice Guidelines for Sentinel Lymph Node Biopsy in Breast Cancer Patients. 2014 November 25 [cited 2020 May 5]. Available from:http://www.breastsurgeons.org/resources/statements

McMasters KM, Wong SL, Chao C, Woo C, Tuttle TM, Noyes RD,et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001; 234:292-9.

Simmons RM. Review of sentinel lymph node credentialing:how many cases are enough?. J Am Coll Surg 2001;193:206-9.

Feldman SM, Krag DN, McNally RK, Moor BB, Weaver DL, Klein P. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 1999;188:248-54.

Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 2000; 7:21-7.

Sandra LW, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ,et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 2002; 9:272–277.

Ratanachaikanont T, Karalak A. Sentinel node localization in breast cancer using intradermal dye injection:results, influencing factors and learning curve. J Med Assoc Thai 2005; 88:386–90.

Kantaraksa N, Kongdan Y, Suvikapakornkul R, Wasutit Y,Chirappapha P, Lertsithichai P. The relative false negative rate of isosulfan blue in detecting sentinel lymph nodes in early breast cancer. J Med Assoc Thai 2012;95:181-5.

Ratchaworapong K, Thanawut S, Yodavudh S, Chottanapund S. Rate of sentinel lymph node identification using isosulfan blue dye in breast cancer patients at Charoenkrung Pracharak Hospital, Thailand. Asian Biomedicine 2014;8:517-24.

Panawattanakul R. False negative rate of sentinel lymph node biopsy in patient with early breast cancer in Udonthani hospital.Udonthani Hospital Medical Journal 2018;26:1–8.

Published

2021-11-30

How to Cite

1.
Areerattanavet ก. Identification Rate of Sentinel Lymph Node Biopsy using Single Technique (Isosulfan Blue Dye) in Early Breast Cancer in Lopburi Cancer Hospital. j dept med ser [Internet]. 2021 Nov. 30 [cited 2022 May 18];46(3):73-80. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/255156

Issue

Section

Original Article